Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement

Int J Hematol. 2014 Jul;100(1):7-15. doi: 10.1007/s12185-014-1607-x. Epub 2014 Jun 13.

Abstract

Iron overload is common in myelodysplastic syndrome (MDS) patients, and an accumulation of evidence shows that iron chelation may have benefits in these patients. However, discussion and consensus about iron chelation therapy (ICT) for MDS patients is lacking in Taiwan and other Southeast Asian countries. An Expert Panel in Taiwan was organized in 2011 to develop iron overload guidelines and provide a uniform reference for physicians treating MDS patients with iron overload, with specific regard to when to initiate ICT, in which patients, and the clinical and scientific rationale behind its use.

MeSH terms

  • Chelation Therapy / methods
  • Hematopoiesis / drug effects
  • Humans
  • Iron Chelating Agents / therapeutic use
  • Iron Overload / complications
  • Iron Overload / drug therapy*
  • Iron Overload / etiology*
  • Myelodysplastic Syndromes / complications*
  • Myelodysplastic Syndromes / epidemiology
  • Practice Guidelines as Topic
  • Survival Analysis
  • Taiwan / epidemiology

Substances

  • Iron Chelating Agents